Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug MK-1045 enters early safety testing for lupus and arthritis

NCT ID NCT07363590

First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 16 times

Summary

This early-stage study tests a new medicine called MK-1045 in 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and tolerable at different doses. Participants must have had their condition for at least 6 months and be on standard treatment. This is not a cure; it aims to manage disease symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anima Diepenbeek ( Site 0601)

    RECRUITING

    Diepenbeek, Limburg, 3590, Belgium

    Contact Phone: •••-•••-••••

  • Arensia Exploartory Medicine ( Site 1301)

    RECRUITING

    Tbilisi, 0112, Georgia

    Contact Phone: •••-•••-••••

  • Istituto Clinico Humanitas- IRCCS ( Site 1902)

    RECRUITING

    Rozzano, Milano, 20089, Italy

    Contact Phone: •••-•••-••••

  • PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001)

    RECRUITING

    Chisinau, 2025, Moldova

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.